Cite
Luginbuhl AJ, Johnson JM, Harshyne LA, et al. Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma. Clin Cancer Res. 2021;doi: 10.1158/1078-0432.CCR-21-1816.
Luginbuhl, A. J., Johnson, J. M., Harshyne, L. A., Linnenbach, A. J., Shukla, S. K., Alnemri, A., Kumar, G., Cognetti, D. M., Curry, J. M., Kotlov, N., Antysheva, Z., Degryse, S., Mannion, K., Gibson, M. K., Netterville, J., Brown, B., Axelrod, R., Zinner, R., Tuluc, M., Gargano, S., Leiby, B. E., Shimada, A., Mahoney, M. G., Martinez-Outschoorn, U., Rodeck, U., Kim, Y. J., South, A. P., & Argiris, A. (2021). Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, . https://doi.org/10.1158/1078-0432.CCR-21-1816
Luginbuhl, Adam J, et al. "Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma." Clinical cancer research : an official journal of the American Association for Cancer Research vol. (2021). doi: https://doi.org/10.1158/1078-0432.CCR-21-1816
Luginbuhl AJ, Johnson JM, Harshyne LA, Linnenbach AJ, Shukla SK, Alnemri A, Kumar G, Cognetti DM, Curry JM, Kotlov N, Antysheva Z, Degryse S, Mannion K, Gibson MK, Netterville J, Brown B, Axelrod R, Zinner R, Tuluc M, Gargano S, Leiby BE, Shimada A, Mahoney MG, Martinez-Outschoorn U, Rodeck U, Kim YJ, South AP, Argiris A. Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma. Clin Cancer Res. 2021 Dec 15; doi: 10.1158/1078-0432.CCR-21-1816. Epub 2021 Dec 15. PMID: 34911681.
Copy
Download .nbib